Tonix Pharmaceuticals Holding Corp. (TNXP) stock
TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3083% below fair value
$2.82−0.12 (-4.08%)
Close on Nov 18, 2026Market cap $48.37MP/E –Yield –
Tonix Pharmaceuticals operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
Tonix Pharmaceuticals's operating income for the twelve months ending Jun 30, 2026 was -$165.43M. For fiscal 2025 it was -$125.70M. The highest annual figure on record is -$1.93M in fiscal 2010.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$125.70M | – |
| FY2024 | Dec 31, 2024 | -$136.70M | – |
| FY2023 | Dec 31, 2023 | -$118.38M | – |
| FY2022 | Dec 31, 2022 | -$112.09M | – |
| FY2021 | Dec 31, 2021 | -$92.31M | – |
| FY2020 | Dec 31, 2020 | -$50.51M | – |
| FY2019 | Dec 31, 2019 | -$28.83M | – |
| FY2018 | Dec 31, 2018 | -$26.32M | – |
| FY2017 | Dec 31, 2017 | -$21.29M | – |
| FY2016 | Dec 31, 2016 | -$38.97M | – |
| FY2015 | Dec 31, 2015 | -$48.16M | – |
| FY2014 | Dec 31, 2014 | -$27.66M | – |
| FY2013 | Dec 31, 2013 | -$10.89M | – |
| FY2012 | Dec 31, 2012 | -$6.66M | – |
| FY2011 | Dec 31, 2011 | -$3.38M | – |
| FY2010 | Dec 31, 2010 | -$1.93M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$42.54M | – |
| Q1 FY2026 | Mar 31, 2026 | -$41.54M | – |
| Q4 FY2025 | Dec 31, 2025 | -$48.29M | – |
| Q3 FY2025 | Sep 30, 2025 | -$33.07M | – |
| Q2 FY2025 | Jun 30, 2025 | -$28.30M | – |
| Q1 FY2025 | Mar 31, 2025 | -$16.05M | – |
| Q4 FY2024 | Dec 31, 2024 | -$22.48M | – |
| Q3 FY2024 | Sep 30, 2024 | -$15.55M | – |
| Q2 FY2024 | Jun 30, 2024 | -$77.32M | – |
| Q1 FY2024 | Mar 31, 2024 | -$21.35M | – |
| Q4 FY2023 | Dec 31, 2023 | -$27.33M | – |
| Q3 FY2023 | Sep 30, 2023 | -$28.15M | – |
| Q2 FY2023 | Jun 30, 2023 | -$29.00M | – |
| Q1 FY2023 | Mar 31, 2023 | -$33.90M | – |
| Q4 FY2022 | Dec 31, 2022 | -$32.73M | – |
| Q3 FY2022 | Sep 30, 2022 | -$29.59M | – |
| Q2 FY2022 | Jun 30, 2022 | -$23.34M | – |
| Q1 FY2022 | Mar 31, 2022 | -$26.44M | – |
| Q4 FY2021 | Dec 31, 2021 | -$29.48M | – |
| Q3 FY2021 | Sep 30, 2021 | -$18.54M | – |
| Q2 FY2021 | Jun 30, 2021 | -$23.56M | – |
| Q1 FY2021 | Mar 31, 2021 | -$20.74M | – |
| Q4 FY2020 | Dec 31, 2020 | -$17.02M | – |
| Q3 FY2020 | Sep 30, 2020 | -$12.00M | – |
| Q2 FY2020 | Jun 30, 2020 | -$14.19M | – |
| Q1 FY2020 | Mar 31, 2020 | -$7.30M | – |
| Q4 FY2019 | Dec 31, 2019 | -$8.73M | – |
| Q3 FY2019 | Sep 30, 2019 | -$7.89M | – |
| Q2 FY2019 | Jun 30, 2019 | -$5.91M | – |
| Q1 FY2019 | Mar 31, 2019 | -$6.30M | – |
| Q4 FY2018 | Dec 31, 2018 | -$7.65M | – |
| Q3 FY2018 | Sep 30, 2018 | -$5.54M | – |
| Q2 FY2018 | Jun 30, 2018 | -$6.14M | – |
| Q1 FY2018 | Mar 31, 2018 | -$6.99M | – |
| Q4 FY2017 | Dec 31, 2017 | -$5.54M | – |
| Q3 FY2017 | Sep 30, 2017 | -$5.84M | – |
| Q2 FY2017 | Jun 30, 2017 | -$4.82M | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.09M | – |
| Q4 FY2016 | Dec 31, 2016 | -$7.51M | – |
| Q3 FY2016 | Sep 30, 2016 | -$7.61M | – |
See a number that looks wrong?